S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:ALLK

Allakos - ALLK Stock Forecast, Price & News

$4.61
-0.12 (-2.54%)
(As of 03/24/2023 08:50 PM ET)
Add
Compare
Today's Range
$4.51
$4.78
50-Day Range
$4.61
$8.11
52-Week Range
$2.54
$8.73
Volume
757,300 shs
Average Volume
978,975 shs
Market Capitalization
$394.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.75

Allakos MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
220.0% Upside
$14.75 Price Target
Short Interest
Bearish
7.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.24) to ($2.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

324th out of 995 stocks

Pharmaceutical Preparations Industry

141st out of 482 stocks


ALLK stock logo

About Allakos (NASDAQ:ALLK) Stock

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

Where Allakos Stands With Analysts
Why Allakos Stock Was Heating Up Today
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Why Is Allakos (ALLK) Stock Soaring 25% Today?
See More Headlines
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Company Calendar

Last Earnings
3/06/2023
Today
3/27/2023
Next Earnings (Estimated)
5/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.75
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+220.0%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-319,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.64 per share

Miscellaneous

Free Float
57,193,000
Market Cap
$394.98 million
Optionable
Not Optionable
Beta
0.50

Key Executives

  • Robert AlexanderRobert Alexander
    Chief Executive Officer & Director
  • Adam L. Tomasi
    President
  • Scott Hirsch
    Chief Operating Officer
  • Harlan Baird Radford
    Chief Financial Officer
  • Craig Paterson
    Chief Medical Officer













ALLK Stock - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings
or view top-rated stocks.

What is Allakos' stock price forecast for 2023?

5 brokerages have issued 1 year price objectives for Allakos' stock. Their ALLK share price forecasts range from $7.00 to $22.00. On average, they predict the company's share price to reach $14.75 in the next year. This suggests a possible upside of 220.0% from the stock's current price.
View analysts price targets for ALLK
or view top-rated stocks among Wall Street analysts.

How have ALLK shares performed in 2023?

Allakos' stock was trading at $8.42 on January 1st, 2023. Since then, ALLK shares have decreased by 45.2% and is now trading at $4.61.
View the best growth stocks for 2023 here
.

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our ALLK earnings forecast
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Monday, March, 6th. The company reported ($0.50) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.50).

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (1.47%), Braidwell LP (1.08%), Millennium Management LLC (0.98%), Geode Capital Management LLC (0.85%), Renaissance Technologies LLC (0.79%) and Citigroup Inc. (0.74%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends
.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $4.61.

How much money does Allakos make?

Allakos (NASDAQ:ALLK) has a market capitalization of $394.98 million. The company earns $-319,950,000.00 in net income (profit) each year or ($5.53) on an earnings per share basis.

How many employees does Allakos have?

The company employs 192 workers across the globe.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.

This page (NASDAQ:ALLK) was last updated on 3/27/2023 by MarketBeat.com Staff